Health Care [ 5/12 ] | Biotechnology [ 29/74 ]
NYSE MKT | Common Stock
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.
The company is based in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 24 | -11.52 Decreased by -1.10 K% | -11.52 |
| Aug 13, 24 | 5.34 Increased by +1.30 K% | -13.68 Increased by +139.00% |
| May 14, 24 | -0.28 Decreased by -1.34 K% | -0.31 Increased by +9.68% |
| Mar 29, 24 | -0.71 Decreased by -26.40 K% | -0.40 Decreased by -77.50% |
| Nov 13, 23 | 1.15 Increased by +2.32 K% | -0.53 Increased by +316.98% |
| Aug 30, 23 | -0.44 Decreased by -918.48% | - |
| May 31, 23 | -0.02 Decreased by -124.13% | - |
| Dec 31, 22 | 0.00 Decreased by -62.50% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -6.17 M Increased by +65.02% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | 164.11 M Increased by +574.82% | Increased by +N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -118.02 M Decreased by -1.03 K% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -15.38 M Decreased by N/A% | Decreased by N/A% - |
| Mar 31, 23 | 0.00 - | -17.64 M - | Decreased by N/A% - |
| Dec 31, 22 | 0.00 - | -34.56 M - | Decreased by N/A% - |
| Sep 30, 22 | 0.00 - | -10.44 M - | Decreased by N/A% - |
| Jun 30, 22 | N/A - | N/A - | - - |